[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551260":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":27,"responsibleParty":44,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Catholic University of the Sacred Heart","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Antiresorptive Drugs",null,"Patients treated by means of Antiresorptive drugs due to either bone metastasis or metabolic diseases",[13],"Procedure: Dental management",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Dental management","The oral conditions of the included patients will be evaluated at baseline. When indicated, dental extractions will be performed before the beginning of Antiresorptive Therapy. Patients will then receive a six-months intervals follow-up, during which primary and secondary prevention of dental diseases will be performed.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Carlo Lajolo, Prof.","CONTACT","3356078354","+39","carlo.lajolo@unicatt.it",[28],{"facility":29,"status":30,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Cosimo Rupe","RECRUITING","Roma","00168","Italy","IT",{"type":36,"coordinates":37},"Point",[38,39],11.10642,44.99364,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":10,"phoneExt":10,"email":10},"Carlo Lajolo",{"type":45,"investigatorFullName":43,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Associate Professor","100551260","medication-related-osteonecrosis-of-the-jaws-mronj-in-a-cohort-of-patients-treated-by-antiresorptive-drugs-100551260",false,"NCT06457776","Medication Related Osteonecrosis of the Jaws (MRONJ) in a Cohort of Patients Treated by Antiresorptive Drugs","Medication Related Osteonecrosis of the Jaws (MRONJ) in a Cohort of Patients Treated by Antiresorptive Drugs: a Cohort Prospective Study","Inclusion Criteria:\n\n* Patients with specific prescription to initiate therapy with antiresorptive drugs\n\nExclusion Criteria:\n\n* Previous Head and Neck Radiotherapy","ALL","18 Years",{"count":57,"type":58},126,"ESTIMATED","OBSERVATIONAL","The objective of this prospective observational study is to investigate the incidence of Medication Related Osteonecrosis of the Jaws (MRONJ) in patients receiving antiresorptive drugs for oncohematologic reasons during a 5-year follow-up. Secondary objectives are to compare the different antiresorptive drugs in relation to the incidence of MRONJ and to identify any systemic as well as local risk factors.",[62,63,64,65,66],"Osteonecrosis of the Jaw","Osteonecrosis Due to Drugs, Jaw","Osteonecrosis Due to Drug","Bisphosphonate-Associated Osteonecrosis","Bisphosphonate-Associated Osteonecrosis of the Jaw","2024-06-17",{"date":69,"type":70},"2024-06-20","ACTUAL",{"date":72,"type":70},"2021-01-01",{"date":74,"type":58},"2028-01-01",{"name":5,"class":6},1]